• LAST PRICE
    0.8500
  • TODAY'S CHANGE (%)
    Trending Up0.0675 (8.6262%)
  • Bid / Lots
    0.8010/ 8
  • Ask / Lots
    0.8409/ 2
  • Open / Previous Close
    0.8509 / 0.7825
  • Day Range
    Low 0.8000
    High 0.9199
  • 52 Week Range
    Low 0.6300
    High 3.2300
  • Volume
    2,992
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.7825
TimeVolumeESLA
09:33 ET1000.8509
09:35 ET9000.8799
09:42 ET2290.842
10:04 ET1000.85
10:40 ET2000.8
10:51 ET1000.8
02:59 ET1830.85
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesESLA
Estrella Immunopharma Inc
28.3M
-4.3x
---
United StatesENLV
Enlivex Therapeutics Ltd
27.8M
-1.1x
---
United StatesINKT
Mink Therapeutics Inc
28.8M
-1.5x
---
United StatesMIRA
Mira Pharmaceuticals Inc
27.3M
-2.2x
---
United StatesCLCS
Cell Source Inc
27.3M
-4.0x
---
United StatesAKTX
Akari Therapeutics PLC
29.5M
-0.8x
---
As of 2024-11-05

Company Information

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Contact Information

Headquarters
5858 Horton Street, Suite 370EMERYVILLE, CA, United States 94608
Phone
510-318-9098
Fax
847-827-5303

Executives

Chairman of the Board
Hong Zhang
Chief Executive Officer, Director
Cheng Liu
Chief Financial Officer, Company Secretary
Luqi Wen
Director
Marsha Roberts
Director
Fan Wu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$28.3M
Revenue (TTM)
$0.00
Shares Outstanding
36.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.20
Book Value
$0.12
P/E Ratio
-4.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.